Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer  

作　　者：Nicholas C Turner 

机构地区：[1]不详

出　　处：《四川生理科学杂志》2024年第11期2501-2501,共1页

摘　　要：Background:Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex(encoded by PIK3CA)that also promotes the degradation of mutated p110α.Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials.

关 键 词：PIK3CA BREAST CANCER 

分 类 号：R73[医药卫生—肿瘤]